• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Systemic factors may not be predictive of VA outcomes for diabetic patients after cataract surgery

Article

A team of investigators evaluated VA outcomes after cataract surgery and the factors associated with good visual outcomes in a population of patients diagnosed with type 2 diabetes.

Investigators found that for patients diagnosed with diabetes, systemic parameters may not be as valuable as the ocular parameters in helping to evaluate the visual acuity prognosis following cataract surgery.

Investigators found that for patients diagnosed with diabetes, systemic parameters may not be as valuable as the ocular parameters in helping to evaluate the visual acuity prognosis following cataract surgery.

For patients diagnosed with diabetes, systemic parameters may not be as valuable as the ocular parameters in helping to evaluate the visual acuity (VA) prognosis after cataract surgery, according to research1 by Debora Lee, MD, and colleagues from the Division of Epidemiology and Clinical Applications, National Eye Institute, Bethesda, Maryland.

The investigators evaluated VA outcomes after cataract surgery and the factors associated with good visual outcomes in a population of patients diagnosed with type 2 diabetes. The patients were enrolled in The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and ACCORD-eye substudy. The study included 1136 eyes of 784 ACCORD participants who underwent cataract surgery during a follow-up period from 2001 to 2014.

Of those eyes, 362 eyes had fundus photographs gradable for diabetic retinopathy. The main outcome measure was a postoperative VA of 20/40 or better.

Analysis of diabetic patients post-cataract surgery

The results showed that two-thirds of eyes achieved good visual outcomes following cataract surgery.

The investigators found that the factors that predicted good VA outcomes were a higher level of education, i.e., college versus some high school (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.44-3.82), bilateral cataract surgery (OR, 1.55; 95% CI, 1.14-2.10), and preoperative VAs of 20/20 or better versus worse than 20/200 (OR, 10.59; 95% CI, 4.07-27.54).

Age, sex, race, smoking, diabetes duration, blood pressure, lipid levels, and hemoglobin A1C (HbA1C) were not correlated significantly with visual outcomes.

In the 362 eyes with gradable fundus photographs, the absence of diabetic retinopathy was associated significantly with good visual outcome (OR, 1.73; 95% CI, 1.02-2.94).

Considering that the HbA1C was not predictive of VA outcomes, the authors commented this finding emphasized that “while certain ocular measures may help evaluate visual potential, systemic parameters may not be as valuable.”

They also added that sociodemographic factors might be important considerations.

“Although the current visual prognosis after cataract surgery is usually favorable, certain factors still limit the visual potential in those with diabetes and continued efforts to improve visual outcomes are necessary,” the investigators concluded.

Reference

1. Lee D, Agron E, Keenan T, et al. on behalf of the ACCORD Eye Study Research Group. Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Br J Ophthalmol. 2022;106 :-ii. Published Online First 20 Oct 2022. http://dx.doi.org/10.1136/bjophthalmol-2020-317793

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.